Beeio Honey Ltd.

Investor Presentation • Dec 6, 2021

This is an English translation of a Hebrew immediate report that was published on December 6 th , 2021 (reference no: 2021-01-176595) (hereafter: the "Hebrew Version"). This English version is only for convenience purposes. This is not an official translation and has no binding force. Whilst reasonable care and skill have been exercised in the preparation hereof, no translation can ever perfectly reflect the Hebrew Version. In the event of any discrepancy between the Hebrew Version and this translation, the Hebrew Version shall prevail.

BEEIO HONEY LTD (the "Company")

December 6th, 2021

To: To: www.isa.gov.il www.tase.co.il

Israel Securities Authority ("ISA") Tel Aviv Stock Exchange Ltd. ("TASE")

Dear Sir and Madam,

Re: Update to Investor's Presentation according to a Conversation with ISA Staff

In accordance with a conversation held by the Company with the staff of the ISA, the Company is honored to update that further to the Company's report of August 26, 2021 (Ref No.: 2021-01- 071794), in which the Company published the half-yearly report for the period ended on June 30, 2021 (the "Periodic Report"), and further to the Company's updated presentation published by the Company on November 29, 2021 (Ref No.: 2021-01-172944) (the "Capital Market Presentation"), the Company updates as follows:

• 1. Further to Section 29 of Chapter A of the Periodic Report under which the Company is expected to increase the production capacity of cultivated honey it develops to a quantity of up to dozens of liters in 2023, and further to the roadmap of the Company's activity on page 27 of the Capital Market Presentation, the Company updates that the projection of increasing the production capacity was brought forward to Q2 2022.
• 1. The above projection's update above derives from the expansion of the Company's development laboratory and recruitment of an additional research and development staff, that assisted to the expedition of the Company's research and development processes.
• 1. In addition, the Company wishes to clarify a few points in connection with the advantages and disadvatages of the cultivated honey it develops as specified on page 15 of the Capital Market Presentation:
  2. 3.1 "Safe for babies to eat" despite the good properties of natural honey, it may trigger some negative physical reactions in babies under one year of age. Pure honey may contain spores of Clostridium Botulinum which are dangerous mainly for babies under one year of age and may cause phenomena such as difficulty in speech and swallowing and later on breathing

difficulties, muscle paralysis, and even death. In addition, in certain cases the nectar composition may lead to the formation of poisonous honey as a result of a neurotoxin the nectar contains named Grayanotoxin. The development method of the Company's cultured honey, under laboratory conditions, will also enable future development of spore- and toxinfree honey that will be adjusted to the special needs of various populations such as babies under one year of age.

• 3.2 "Medical Properties" and "Nutritional Values" the Company wishes to emphasize that while its cultured honey will be developed under laboratory conditions and free of bee use, this is cultured honey that will be similar in composition to natural honey that is produced by honeybees in nature. The Company's cultured honey will retain the medical properties and nutritional values of natural honey, as opposed to honey substitutes which are currently available on the market.
• 3.3 To the Company's estimation, its technology does not consist of major disadvantages compared to natural honey and honey substitutes. Nevertheless, the Company may have to perform market education in order to properly implement cultivated honey as a product, and the company is already working to perform such market education.
• 1. Further to the content of page 16 in the Capital Market Presentation, under the heading "Patents", the Company wishes to clarify that some of the patent applications it filed are provisional patent applications intended to reserve the filing date of the patent applications until the full patent application is filed and the Company acts towards filing full patent applications.

The information mentioned in this notice is "Forward Looking Statement" as defined in The Securities Law, 5728-1968, based on the information known to the Company as of this date, and on estimates and predictions which their realization depends, among others, on factors that are outside of the Company's control. To be noted, the Company is a research and development company and as such, its estimations might be realized in a different manner, if at all, given that the Company's research is preliminary and precedential.

Sincerely,

OFIR DVASH, CEO BEEIO HONEY LTD